Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 7/20 | 0.44 |
| ▸ | FLT4 | P35916 | 7/20 | 0.44 |
| ▸ | KDR | P35968 | 7/20 | 0.44 |
| ▸ | KIT | P10721 | 5/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.39 |
| ▸ | IL2 | P60568 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2828692 | 0.88 | FLT1 (0.49) | FLT1FLT4KDRKITALOX5 | |
| SCHEMBL543888 | 0.81 | ROCK2 (0.53) | CYP2C9 | |
| SCHEMBL2347458 | 0.80 | KIT (0.46) | FLT1FLT4KDRKIT | |
| SCHEMBL544655 | 0.80 | KCNQ3 (0.47) | KDRKITALOX5 | |
| SCHEMBL544248 | 0.80 | ROCK2 (0.52) | KIT | |
| SCHEMBL10065869 | 0.79 | KIT (0.46) | FLT1FLT4KDRKITALOX5 | |
| SCHEMBL544093 | 0.79 | MEN1 (0.50) | FLT1FLT4KDR | |
| SCHEMBL2339077 | 0.79 | KIT (0.48) | FLT1FLT4KDRKITALOX5 | |
| SCHEMBL3299706 | 0.78 | SMN1; SMN2 (0.51) | KDRKIT | |
| SCHEMBL543731 | 0.77 | BRAF (0.51) | KITCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2010-05-06 | — | — | US | disclosed |
| EP-1684750-B1 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2010-04-28 | — | — | EP | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| EP-1684750-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005040139-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | FGFR3, ABL1, FLT3 | FLT1 17/4885FLT4 13/4885KDR 37/4885 |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | FGFR3, FLT3, ABL1 | FLT1 25/4885FLT4 15/4885KDR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.